Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Ascani, S; Massone, C; Ferrara, G; Rongioletti, F; Papini, M; Pileri, S; Cerroni, L.
CD4-negative variant of CD4+/CD56+ hematodermic neoplasm: description of three cases.
J CUTANEOUS PATHOL. 2008; 35(10): 911-915. Doi: 10.1111/j.1600-0560.2007.00915.x (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Cerroni Lorenzo
Co-authors Med Uni Graz: Massone Cesare
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: CD4+/CD56+ hematodermic neoplasm (HN) (blastic natural killer (NK)-cell lymphoma) is a rare entity characterized by dense, monomorphous infiltrates of medium-sized cells with blastic appearance and a characteristic immunophenotype (positivity for CD4, CD56 and CD123). The combination of CD4 and CD56 positivity is thought to be so striking that it has been used to name this entity. METHODS: Three cases of HN with ambiguous phenotypic profile were included in this study. In all cases, phenotypic, molecular and in situ hybridization studies were carried out. RESULTS: All three cases showed an aberrant phenotype with negativity for CD4. CONCLUSIONS: CD4-negative or CD56-negative cases of HN have been rarely reported in the literature and represent a diagnostic problem. Our three cases confirm that CD4 is not always expressed in these neoplasms. The term 'CD4+/CD56+ hematodermic neoplasm' adopted in the World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas may be misleading and should probably be revised in the light of all data published in the literature.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Antigens, CD4 - metabolism; Antigens, CD56 - metabolism; Antineoplastic Agents - therapeutic use; Bone Marrow Transplantation -; Combined Modality Therapy -; Humans -; Immunophenotyping -; In Situ Hybridization -; Killer Cells, Natural - metabolism Killer Cells, Natural - pathology; Lymphoma, Non-Hodgkin - metabolism Lymphoma, Non-Hodgkin - pathology Lymphoma, Non-Hodgkin - therapy; Male -; Radiotherapy -; Skin Neoplasms - metabolism Skin Neoplasms - pathology Skin Neoplasms - therapy; Tumor Markers, Biological - analysis